Zhan et al. demonstrated that the tumor suppressor PTPN13 inhibits the malignant behavior of HCC via its phosphatase function and counteracts the activation of EGFR/ERK signaling, as shown by changes in EMT markers and the malignant phenotype induced by EGF [23]. This evidence concerns the gene PTPN13 and hepatocellular carcinoma.